Overexpression of human apolipoprotein A-II in mice induces hypertriglyceridemia due to defective very low density lipoprotein hydrolysis - PubMed (original) (raw)
. 1999 Apr 23;274(17):11564-72.
doi: 10.1074/jbc.274.17.11564.
G Lambert, V Atger, N Q Tran, D Pastier, C Benetollo, J F Trottier, I Beaucamps, M Antonucci, M Laplaud, S Griglio, J Chambaz, A D Kalopissis
Affiliations
- PMID: 10206963
- DOI: 10.1074/jbc.274.17.11564
Free article
Overexpression of human apolipoprotein A-II in mice induces hypertriglyceridemia due to defective very low density lipoprotein hydrolysis
E Boisfer et al. J Biol Chem. 1999.
Free article
Abstract
Two lines of transgenic mice, hAIItg-delta and hAIItg-lambda, expressing human apolipoprotein (apo)A-II at 2 and 4 times the normal concentration, respectively, displayed on standard chow postprandial chylomicronemia, large quantities of very low density lipoprotein (VLDL) and low density lipoprotein (LDL) but greatly reduced high density lipoprotein (HDL). Hypertriglyceridemia may result from increased VLDL production, decreased VLDL catabolism, or both. Post-Triton VLDL production was comparable in transgenic and control mice. Postheparin lipoprotein lipase (LPL) and hepatic lipase activities decreased at most by 30% in transgenic mice, whereas adipose tissue and muscle LPL activities were unaffected, indicating normal LPL synthesis. However, VLDL-triglyceride hydrolysis by exogenous LPL was considerably slower in transgenic compared with control mice, with the apparent Vmax of the reaction decreasing proportionately to human apoA-II expression. Human apoA-II was present in appreciable amounts in the VLDL of transgenic mice, which also carried apoC-II. The addition of purified apoA-II in postheparin plasma from control mice induced a dose-dependent decrease in LPL and hepatic lipase activities. In conclusion, overexpression of human apoA-II in transgenic mice induced the proatherogenic lipoprotein profile of low plasma HDL and postprandial hypertriglyceridemia because of decreased VLDL catabolism by LPL.
Similar articles
- Human apolipoprotein A-II determines plasma triglycerides by regulating lipoprotein lipase activity and high-density lipoprotein proteome.
Julve J, Escolà-Gil JC, Rotllan N, Fiévet C, Vallez E, de la Torre C, Ribas V, Sloan JH, Blanco-Vaca F. Julve J, et al. Arterioscler Thromb Vasc Biol. 2010 Feb;30(2):232-8. doi: 10.1161/ATVBAHA.109.198226. Epub 2009 Nov 12. Arterioscler Thromb Vasc Biol. 2010. PMID: 19910634 - Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles.
Aalto-Setälä K, Fisher EA, Chen X, Chajek-Shaul T, Hayek T, Zechner R, Walsh A, Ramakrishnan R, Ginsberg HN, Breslow JL. Aalto-Setälä K, et al. J Clin Invest. 1992 Nov;90(5):1889-900. doi: 10.1172/JCI116066. J Clin Invest. 1992. PMID: 1430212 Free PMC article. - Human ApoA-II inhibits the hydrolysis of HDL triglyceride and the decrease of HDL size induced by hypertriglyceridemia and cholesteryl ester transfer protein in transgenic mice.
Zhong S, Goldberg IJ, Bruce C, Rubin E, Breslow JL, Tall A. Zhong S, et al. J Clin Invest. 1994 Dec;94(6):2457-67. doi: 10.1172/JCI117614. J Clin Invest. 1994. PMID: 7989603 Free PMC article. - Paradoxical exacerbation of combined hyperlipidemia in human apolipoprotein A-II transgenic mice treated with fenofibrate.
Ribas V, Palomer X, Roglans N, Rotllan N, Fievet C, Tailleux A, Julve J, Laguna JC, Blanco-Vaca F, Escolà-Gil JC. Ribas V, et al. Biochim Biophys Acta. 2005 Dec 15;1737(2-3):130-7. doi: 10.1016/j.bbalip.2005.09.009. Epub 2005 Sep 30. Biochim Biophys Acta. 2005. PMID: 16226489 - Role of apoA-II in lipid metabolism and atherosclerosis: advances in the study of an enigmatic protein.
Blanco-Vaca F, Escolà-Gil JC, Martín-Campos JM, Julve J. Blanco-Vaca F, et al. J Lipid Res. 2001 Nov;42(11):1727-39. J Lipid Res. 2001. PMID: 11714842 Review.
Cited by
- Apolipoprotein A-II, a Player in Multiple Processes and Diseases.
Florea G, Tudorache IF, Fuior EV, Ionita R, Dumitrescu M, Fenyo IM, Bivol VG, Gafencu AV. Florea G, et al. Biomedicines. 2022 Jul 2;10(7):1578. doi: 10.3390/biomedicines10071578. Biomedicines. 2022. PMID: 35884883 Free PMC article. Review. - Dietary acid load modifies the effects of ApoA2-265 T > C polymorphism on lipid profile and serum leptin and ghrelin levels among type 2 diabetic patients.
Abaj F, Esmaeily Z, Naeini Z, Rafiee M, Koohdani F. Abaj F, et al. BMC Endocr Disord. 2022 Jul 26;22(1):190. doi: 10.1186/s12902-022-01083-7. BMC Endocr Disord. 2022. PMID: 35883173 Free PMC article. - Anorexia Nervosa Is Associated with a Shift to Pro-Atherogenic Low-Density Lipoprotein Subclasses.
Stadler JT, Lackner S, Mörkl S, Meier-Allard N, Scharnagl H, Rani A, Mangge H, Zelzer S, Holasek SJ, Marsche G. Stadler JT, et al. Biomedicines. 2022 Apr 13;10(4):895. doi: 10.3390/biomedicines10040895. Biomedicines. 2022. PMID: 35453644 Free PMC article. - Posttranslational modifications of apolipoprotein A-II proteoforms in type 2 diabetes.
Azizkhanian I, Trenchevska O, Bashawri Y, Hu J, Koska J, Reaven PD, Nelson RW, Nedelkov D, Yassine HN. Azizkhanian I, et al. J Clin Lipidol. 2016 Jul-Aug;10(4):808-815. doi: 10.1016/j.jacl.2016.03.001. Epub 2016 Mar 8. J Clin Lipidol. 2016. PMID: 27578111 Free PMC article. - D25V apolipoprotein C-III variant causes dominant hereditary systemic amyloidosis and confers cardiovascular protective lipoprotein profile.
Valleix S, Verona G, Jourde-Chiche N, Nédelec B, Mangione PP, Bridoux F, Mangé A, Dogan A, Goujon JM, Lhomme M, Dauteuille C, Chabert M, Porcari R, Waudby CA, Relini A, Talmud PJ, Kovrov O, Olivecrona G, Stoppini M, Christodoulou J, Hawkins PN, Grateau G, Delpech M, Kontush A, Gillmore JD, Kalopissis AD, Bellotti V. Valleix S, et al. Nat Commun. 2016 Jan 21;7:10353. doi: 10.1038/ncomms10353. Nat Commun. 2016. PMID: 26790392 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical